ABREVIATURAS Y SIMBOLOS

ADN Ácido desoxiribonucleico

AV Aurioventricular

E Especificidad

ELISAm ELISA modificada

ELISAc ELISA convencional

EP Concordancia esperada por azar

IFIm Inmunofluorescencia Indirecta Modificada IFIc Inmunofluorescencia Indirecta Convencional HAI Hemaglutinación indirecta

IgG Inmunoglobulina G

IgM Inmunoglobulina M

K Indice Kappa

LCR Líquido cefalorraquídeo

LR+ Razón de verosimilitud positiva LR- Razón de verosimilitud negativa OMS Organización Mundial de la Salud ORD Odds Ratio Diagnóstico

PCR S35-S36 Reacción en Cadena de la Polimerasa S35-S36

T. cruzi Trypanosoma cruzi

TVP Tasas de verdaderos positivos TVN Tasa de verdaderos negativo TFN Tasa de falsos negativos TFP Tasa de falsos positivos

VP Verdaderos positivos

VN Verdaderos negativos

BIBLIOGRAFIA

(1) Enciso C, Montilla MSMM, Nicholls RS, Rodriguez A, Mercado M, Puerta C. Comparación de la prueba de Inmunofluorescencia Indirecta (IFI), un inmunoensayo enzimatico (ELISA) y la prueba comercial CHAGATEK para la detección de anticuerpos contra Trypanosoma cruzi. Biomédica 2004; 24(1):104-108.

(2) Tentori MC. Etiology, Pathophysiology, and Diagnosis of Chagas' Disease. In: Segura E, editor. Arrhythmia Management in Chagas' Disease. Buenos Aires: FUTURA PUBLISHING CO, 2000.

(3) Botero D, Restrepo M. Tripanosomiasis. In: Botero D, Restrepo M, editors. Parasitosis Humanas. Medellín: Corporación para la investigación biolígica, 2003: 239-260

(4) Gulh F, Nichols S. Manual de procedimientos para el diagnóstico de la Enfermedad de Chagas. Bogotá: 2001

(5) Organización Mundial de la Salud. Control of Chagas disease, Second report of the WHO Expert Committee. 905, 39-40. 2002. Ref Type: Report

(6) Moncayo A. Chagas disease: Current Epidemiological Trenes alter the interruption of Vectorial and Transfusional Transmisión in the Southern Cone contraes. Mem Inst Oswaldo Cruz. 2003;98(5):577-591.

(7) Thomas MC, Fernández A, Moro A, García S J, González A. Biología Molecular de los Tripanosomátidos. In: Luis Rivas López, Manuel Carlos López López, editors. Parasitología Molecular. Madrid: 1993: 135-143.

(8) Jaramillo N, Moreno J, Triana O, Arcos-Burgos M, Munoz S, Solari A. Genetic structure and phylogenetic relationships of Colombian Trypanosoma cruzi populations as determined by schizodeme and isoenzyme markers. Am J Trop Med Hyg 1999; 61(6):986-993.

(9) Segura E. Etiology, Patophisiology and diagnosis of chagas disease. In: Tentori MC, Segura E, Hayes DL, editors. Arrhythmia Management in Chagas disease. Futura Publishing Company, 2000: 5-18.

(10) Tanowitz HB, Kirchhoff LV, Simon D, Morris SA, Weiss LM, Wittner M. Chagas' disease. Clin Microbiol Rev 1992; 5(4):400-419.

(11) Organización Mundial de la Salud. The control of Chagas disease. 811. 1991. Ref Type: Report

(12) Lopez AF, Flores RH, Ramos C. Diagnosis of Chagas Disease. Revista Latinoamericana de Microbiología 2000; 42:121-129.

(13) Noya O, Patarroyo ME, Guzman F, Alarcon DN. Immunodiagnosis of parasitic diseases with synthetic paptides. Curr Protein Pept Sci 2003; 4(4):299-308.

(14) Meira WS, Galvao LM, Gontijo ED, Machado-Coelho GL, Norris KA, Chiari E. Trypanosoma cruzi recombinant complement regulatory protein: a novel antigen for use in an enzyme-linked immunosorbent assay for diagnosis of Chagas' disease. J Clin Microbiol 2002; 40(10):3735-3740.

recombinant proteins: results of a collaborative study in six Latin American countries. J Clin Microbiol 2004; 42(1):449-452.

(16) Begoña B F. Validez de las pruebas diagnósticas. In: Gobierno de Navarra.departamento de salud, editor. Epidemiología Clínica aplicada a la toma de decisiones en medicina. Pamplona: 2001: 69-108

(17) Fernandez AF, Alonso MJ, Perez V. Métodos de investigación en cardiología clínica. Estudio de la evaluación de las pruebas diagnósticas en cardiología. Puesta al día. 1998.

(18) Diamond GA. Clinical epistemology of sensitivity and specificity. J Clin Epidemiol 1992; 45(1):9-13

(19) Kramer MS, Feinstein AR. Clinical biostatistics. LIV. The biostatistics of concordance. Clin Pharmacol Ther 1981; 29(1):111-123

(20) Faraone SV, Tsuang MT. Measuring diagnostic accuracy in the absence of a "gold standard". Am J Psychiatry 1994; 151(5):650-657.

(21) Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Interpretación de los datos diagnósticos. Epidemiología clínica. Mexico: Editorial Médica Panamericana, 1998: 80-157

(22) Janssens AC, Deng Y, Borboom GJ, Eijkemans MJ, Habbema JD, Steyerberg EW. A new logistic regresion approach for the evaluation of diagnositic test result. Med Decis Making 2005; 25(2):168-177

(23) CoughlinS S, Trock BCMH, Pickle LW, Browner D, Tefft MC. The logistic modeling of sensitivity, specificity, and predictive value of a diagnostic test. J Clin Epidemiol 1992; 45(1):1-7.

(24) Irwig L. Modeling result-specific likelihood ratios. J Clin Epidemiol 1992; 45(11):1335-1338.

(25) Sullivan PM, Janes H, Longton L, Leisenring W, and Newcomb P. Limitations of the Odds ratio in Gauging the performance of a dignostic, pronostic or screening maker. American Journal of Epidemiology 2004; 159(9):882-890

(26) Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003; 56(11):1129-1135

(27) Garrett ES, Eaton WW, Zeger S. Methods for evaluating the performance of diagnostic tests in the absence of a gold standard: a latent class model approach. Stat Med 2002; 21(9):1289-1307.

(28) Yang I, Becker MP. Latent variable modeling of diagnostic accuracy. Biometrics 1997; 56(11):1129-1135.

(29) Hawkins DM, Garrett JA, Stephenson B. Some issues in resolution of diagnostic tests using an imperfect gold standard. Stat Med 2001; 20(13):1987-2001.

(30) Black MA, Craig BA. Estimating disease prevalence in the absence of a gold standard. Stat Med 2002; 21(18):2653-2669

(31) Alonzo TA, Pepe MS, Moskowitz CS. Sample size calculations for comparative studies of medical tests for detecting presence of disease. Stat Med 2002; 21(6):835- 852.

(31) Biggerstaff BJ. Comparing diagnostic tests: a simple graphic using likelihood ratios. Stat Med 2000; 19(5):649-663.

(33) Lui KJ, Cumberland WG. Sample size determination for equivalence test using rate ratio of sensitivity and specificity in paired sample data. Control Clin Trials 2001; 22(4):373-389

(34) Newcombe RG. Simultaneous comparison of sensitivity and specificity of two tests in the paired design: a straightforward graphical approach. Stat Med 2001; 20(6):907-915

(35) Gulh F, Jaramillo C, Carranza JC, Vallejo GA. Molecular characterization and diagnosis of trypanosoma cruzi and T. rangeli. Arch Med Res 2002; 33(4):362-370. (36) Vallejo GA, Guhl F, Carranza JC, Lozano LE, Sanchez JL, Jaramillo JC et al. kDNA

markers define two major Trypanosoma rangeli lineages in Latin-America. Acta Trop 2002; 81(1):77-82.

(37) Pavìa P, Cuervo C, Montilla M, Nicholls S, Puerta C. Diseño y estandarización de una prueba de PCR para la deteccion especifica de Tripanosoma cruzi. Infectio 2003; 17:129-136.

(38) Vallejo GA. Estudios comparativos entre las secuencias de kADN de T. cruzi y T. rangeli y su aplicación en el diagnóstico molecular de la Tripanosomiasis Americana. Actual Biol 1998; 20:43-56.

(39) Sambrook J, Russell. Gel electrophoresis of DNA. Molecular cloning A Laboratory Manual. 3 Edition. Cold Spring Harbor Laboratory. New York: 2001: 6-19.

(40) Sturm NR, Degrave W, Morel C, Simpson L. Sensitive detection and schizodeme classification of Trypanosoma cruzi cells by amplification of kinetoplast minicircle DNA sequences: use in diagnosis of Chagas' disease. Mol Biochem Parasitol 1989; 33(3):205-214.

(41) Camargo ME, Segura EL, Kagan IG, Souza JM, Carvalheiro JR, Yanovsky JF et al. Three years of collaboration on the standardization of Chagas' disease serodiagnosis in the Americas: an appraisal. Bull Pan Am Health Organ 1986; 20(3):233-244. (42) Brashear RJ, Winkler MA, Schur JD, Lee H, Burczak JD, Hall HJ et al. Detection of

antibodies to Trypanosoma cruzi among blood donors in the southwestern and western United States. I. Evaluation of the sensitivity and specificity of an enzyme immunoassay for detecting antibodies to T. cruzi. Transfusion 1995; 35(3):213-218. (43) Gutierrez R, Angulo VM, Tarazona Z, Britto C, Fernandes O. Comparison of four

serological tests for the diagnosis of Chagas disease in a Colombian endemic area. Parasitology 2004; 129(Pt 4):439-444.

(44) Partel CD, Rossi CL. A rapid, quantitative enzyme-linked immunosorbent assay (ELISA) for the immunodiagnosis of Chagas' disease. Immunol Invest 1998; 27(1- 2):89-96.

(45) Chiari E. Chagas disease diagnosis using polymerase chain reaction, hemoculture and serologic methods. Mem Inst Oswaldo Cruz 1999; 94 Suppl 1:299-300.

(46) Blejer JL, Saguier MC, Salamone HJ. Antibodies to Trypanosoma cruzi among blood donors in Buenos Aires, Argentina. Int J Infect Dis 2001; 5(2):89-93

(47) Lorca M, Child R, Garcia A, Silva M, Osorio J, Atias A. [Evaluation of commercially available reagents for diagnosis of chagas disease in Chilean blood banks. I. Selection of reagents]. Rev Med Chil 1992; 120(4):420-426

(48) Oelemann WM, Teixeira MD, Verissimo Da Costa GC, Borges-Pereira J, De Castro JA, Coura JR et al. Evaluation of three commercial enzyme-linked immunosorbent assays for diagnosis of Chagas' disease. J Clin Microbiol 1998; 36(9):2423-2427. (49) Lopez M, Duque S, Orozco L, Camargo D, Gualdrón L, Cáceres E et al.

(50) Gomes ML, Galvao LM, Macedo AM, Pena SD, Chiari E. Chagas' disease diagnosis: comparative analysis of parasitologic, molecular, and serologic methods. Am J Trop Med Hyg 1999; 60(2):205-210.

(51) Pirard M, Iihoshi N, Boelaert M, Basanta P, Lopez F, Van der Stuyft P. The validity of serologic tests for Trypanosoma cruzi and the effectiveness of transfusional screening strategies in a hyperendemic region. Transfusion 2005; 45(4):554-561.